This recent study, published in the journal Ophthalmology, highlights a potentially groundbreaking shift in how we treat Retinopathy of Prematurity (ROP)—a leading cause of childhood blindness worldwide. Researchers in Sweden investigated whether a simple, low-dose regimen of dexamethasone eye drops could prevent the disease from progressing to the point of requiring invasive surgery or injections.
The Challenge: ROP and Traditional Treatments
Preterm infants are often born with immature retinal blood vessels. In some cases, this leads to ROP, where abnormal vessels grow and can cause retinal detachment. Currently, “traditional” treatments for severe (Type 1) ROP include laser ablation or intravitreal injections of anti-VEGF agents. While effective, these procedures are invasive, often require general anesthesia, and can lead to long-term complications or disease reactivation.
The Study: A Simple Intervention
The study utilized a “difference-in-differences” approach, comparing one Swedish hospital (the intervention site) that introduced dexamethasone drops with three other sites (control sites) that did not.
- The Regimen: Infants diagnosed with Type 2 ROP (a precursor to the more severe Type 1) received a low dose of dexamethasone (1 mg/ml) eye drops, typically one drop per day.
- The Technique: Caregivers were instructed to keep the eyelids apart for 3 to 4 seconds and apply pressure to the nasolacrimal duct to ensure the drug was absorbed and to minimize systemic side effects.
Remarkable Results
The findings suggest that timely administration of these drops significantly halts disease progression:
- Massive Reduction in Surgery: At the intervention site, the need for traditional ROP treatments in infants with severe ROP plummeted from 72% down to just 13%.
- Contrast with Control Groups: During the same period, the control sites (which did not use the drops) actually saw an increase in treatment frequency, from 47% to 56%.
- Statistical Impact: The adjusted interaction odds ratio was 0.05, indicating a markedly larger decline in the need for invasive treatments at the site using dexamethasone.
Safety and Long-Term Outcomes
One of the most promising aspects of this study was the safety profile:
- No Reactivation: Unlike anti-VEGF injections, which can require years of follow-up due to late reactivations, none of the infants treated with dexamethasone showed ROP reactivation three years after screening.
- Side Effects: No cases of cataracts or glaucoma were reported. While one infant showed a temporary increase in intraocular pressure, it normalized without treatment.
Why This Matters for Global Health
The authors conclude that low-dose dexamethasone eye drops could serve as a simple, cost-effective, and non-invasive tool to combat one of the primary causes of visual impairment in children. Because it requires no specialized surgical equipment or anesthesia, this “eye drop first” approach could be particularly transformative in resource-limited settings.
While further randomized controlled trials are currently underway to confirm these findings, this study offers a hopeful new path for neonatal eye care.
Reference:
https://doi.org/10.1016/j.ophtha.2025.09.020 ISSN 0161-6420/25
Interesting study.